Literature DB >> 25586091

Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?

Varun Saxena1, Norah A Terrault.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25586091      PMCID： PMC4422509          DOI： 10.1007/s10620-015-3535-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.

Authors:  Jonathan G Stine; Nicolas Intagliata; Neeral L Shah; Curtis K Argo; Stephen H Caldwell; James H Lewis; Patrick G Northup
Journal:  Dig Dis Sci       Date:  2014-11-06       Impact factor: 3.199

Review 2.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 3.  Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.

Authors:  Jennifer C Price; Norah A Terrault
Journal:  Liver Transpl       Date:  2015-04       Impact factor: 5.799

4.  A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Authors:  Jules L Dienstag; Marc G Ghany; Timothy R Morgan; Adrian M Di Bisceglie; Herbert L Bonkovsky; Hae-Young Kim; Leonard B Seeff; Gyongyi Szabo; Elizabeth C Wright; Richard K Sterling; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S Lok; Chihiro Morishima; Anne M Stoddard; James E Everhart
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

5.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Authors:  G Danan; C Benichou
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

6.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

7.  Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Authors:  Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425
  7 in total
  2 in total

1.  Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.

Authors:  Varun Saxena; Lisa Nyberg; Marypat Pauly; Aditi Dasgupta; Anders Nyberg; Barbara Piasecki; Bradley Winston; Jacquelyn Redd; Joanna Ready; Norah A Terrault
Journal:  Hepatology       Date:  2015-07-30       Impact factor: 17.425

Review 2.  Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.

Authors:  Varun Saxena; Norah Terrault
Journal:  Clin Liver Dis       Date:  2015-07-26       Impact factor: 6.126
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.